LIVACHAR Trademark

Trademark Overview


On Monday, June 3, 2024, a trademark application was filed for LIVACHAR with the United States Patent and Trademark Office. The USPTO has given the LIVACHAR trademark a serial number of 79399431. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, November 5, 2024. This trademark is owned by KOWA COMPANY, LTD.. The LIVACHAR trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of diseases of the circulatory system and diabetes-related diseases, pharmaceutical preparations for treatment of fatty liver and steatohepatitis, pharmaceutical preparations for the treatment of cardiovascular disorders and metabolic disorders, pharmaceutical preparations for the treatment of digestive system disease, pharmaceutical preparations for the treatment of primary biliary cirrhosis, pharmaceutical preparations for the treatment of fatty liver and liver hepatitis and liver cirrhosis, pharmaceutical preparations for the treatment of liver disease, pharmaceutical preparations for the treatment of metabolic disease, pharmaceutical preparations for the prevention and treatment of disorders of the metabolic system, analgesics; pharmaceutical and biological preparations for the treatment of diseases of the central nervous system, peripheral nervous system, sensory organs, the circulatory system, resp...
livachar

General Information


Serial Number79399431
Word MarkLIVACHAR
Filing DateMonday, June 3, 2024
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, November 5, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 5, 2024

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of diseases of the circulatory system and diabetes-related diseases, pharmaceutical preparations for treatment of fatty liver and steatohepatitis, pharmaceutical preparations for the treatment of cardiovascular disorders and metabolic disorders, pharmaceutical preparations for the treatment of digestive system disease, pharmaceutical preparations for the treatment of primary biliary cirrhosis, pharmaceutical preparations for the treatment of fatty liver and liver hepatitis and liver cirrhosis, pharmaceutical preparations for the treatment of liver disease, pharmaceutical preparations for the treatment of metabolic disease, pharmaceutical preparations for the prevention and treatment of disorders of the metabolic system, analgesics; pharmaceutical and biological preparations for the treatment of diseases of the central nervous system, peripheral nervous system, sensory organs, the circulatory system, respiratory system, and the digestive system; pharmaceutical substances for the treatment of dermatological diseases, allergies and urogenital or anal conditions; veterinary preparations, namely, veterinary preparations for the treatment of diseases of the circulatory system and diabetes-related diseases, veterinary preparations for treatment of fatty liver and steatohepatitis, veterinary preparations for the treatment of cardiovascular disorders and metabolic disorders, veterinary preparations for the treatment of digestive system disease, veterinary preparations for the treatment of primary biliary cirrhosis, veterinary preparations for the treatment of fatty liver and liver hepatitis and liver cirrhosis, veterinary preparations for the treatment of liver disease, veterinary preparations for the treatment of metabolic disease, veterinary preparations for the prevention and treatment of disorders of the metabolic system, analgesics; veterinary pharmaceutical and biological preparations for the treatment of diseases of the central nervous system, peripheral nervous system, sensory organs, the circulatory system, respiratory system, and the digestive system; veterinary pharmaceutical substances for the treatment of dermatological diseases, allergies and urogenital or anal conditions; sanitary preparations for medical use; anti-inflammatory agents, namely, topical preparations in the form of gels and salves, adhesive skin patches, liquid formulations, cream and sprays, all for relieving pain.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, July 8, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameKOWA COMPANY, LTD.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressJP

Party NameKOWA COMPANY, LTD.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressJP

Trademark Events


Event DateEvent Description
Monday, July 8, 2024LIMITATION FROM ORIGINAL APPLICATION ENTERED
Tuesday, July 9, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, July 9, 2024APPLICATION FILING RECEIPT MAILED
Monday, September 16, 2024ASSIGNED TO EXAMINER
Tuesday, September 24, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 16, 2024NOTICE OF PUBLICATION
Tuesday, November 5, 2024PUBLISHED FOR OPPOSITION
Friday, July 5, 2024SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB